Voglibose information from DrugsUpdate
P - Contraindicated in pregnancy
L - Contraindicated in lactation
Voglibose, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.
Pharmacodynamics
Pharmacokinetics
Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose.
Voglibose Indications / Voglibose Uses
Information Not Available
Voglibose Adverse Reactions / Voglibose Side Effects
Flatulence; abdominal distension; diarrhoea; pain; skin reactions; hypoglycemia; increased LFT.
Potentially Fatal: Hepatotoxicity.
Precautions
Information Not Available
Special Precautions
History of laparotomy or ileus. Roemheld's syndrome, stenosis, severe hepatic or renal impairment. Child <18 years; elderly. Monitor LFT. Treat hypoglycaemic episodes with glucose (not with sucrose).
Other Drug Interactions
May enhance effects of other antidiabetics including insulin.
Other Interactions
Information Not Available
Dosage
Oral
Diabetes mellitus
Adult: 200-300 mcg tid.
Elderly: Initiate at lower doses.
Food(before/after)
Should be taken with food. (Take just before meals.)
List of Contraindications
Voglibose and Pregnancy
Contraindicated in pregnancy
Voglibose and Lactation
Contraindicated in lactation
Voglibose and Children
Information Not Available
Voglibose and Geriatic
Information Not Available
Voglibose and Other Contraindications
Inflammatory bowel disease; GI obstruction or patients predisposed to it; conditions which may deteriorate as a result of increased gas formation eg, hernia; severe ketosis; diabetic coma or pre-coma; severe infection; hypersensitivity; pregnancy; lactation. Not to be used as monotherapy in IDDM.
Storage
Oral
Store below 30°C.
Lab interference
Oral
Store below 30°C.
Follow us:
